Nasdaq

Vivos Therapeutics Receives FDA 510(k) Clearance of its Flagship DNA Oral Appliance for Treatment of Obstructive Sleep Apnea

LITTLETON, Colo., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for ...
Benzinga.com

Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children

On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, which is used to treat moderate to severe obstructive sleep apnea (OSA) and ...
Yahoo Finance

Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment

LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the ...
Nasdaq

Vivos Reports FDA Clearance Of DNA Oral Appliance

(RTTNews) - Vivos Therapeutics, Inc. (VVOS) announced a brand new clearance from the FDA for its DNA appliance. The company said the FDA 510(k) clearance as a Class II device gives rise to a ...
Healio

FDA grants 510(k) clearance to obstructive sleep apnea treatment device

Please provide your email address to receive an email when new articles are posted on . The FDA has granted 510(k) clearance to a daytime-nighttime appliance, or DNA, to treat patients with mild to ...